Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
-
J Cardiovasc Magn Reson · Jan 2005
Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla.
To evaluate MR safety at 3 Tesla for a drug eluting coronary stent. ⋯ The stent exhibited minor magnetic field interactions that will not cause migration. Heating was not substantial (+0.5 degrees C). Artifacts may create a problem if the area of interest is in the same area or close to the stent (e.g., for a T1-weighted, spin echo pulse sequence, within approximately 16 mm; for a gradient echo pulse sequence, within approximately 23 mm). Conclusion. The findings indicated that it would be safe for a patient with this cobalt alloy-based, drug-eluting coronary stent to undergo MRI at 3 Tesla or less. Importantly, because of the relative lack of magnetic field interactions, MRI may be performed immediately after implantation.
-
This case report describes the diagnosis of Chagas myocarditis in a patient from Honduras who presented with syncope. The discussion summarizes the pathophysiology of cardiac Chagas disease. Acute, latent, and chronic Chagas myocarditis are described. The role of CMR in diagnosing Chagas myocarditis is discussed.
-
J Cardiovasc Magn Reson · Jan 2005
Case ReportsFunctional and metabolic recovery of the right ventricle during Bosentan therapy in idiopathic pulmonary arterial hypertension.
An impaired high-energy phosphate metabolism might play a critical role in the pathogenesis of right ventricular (RV) failure due to chronic pulmonary arterial hypertension (PAH). 31P-NMR spectroscopy is well established for measurements of high-energy phosphate metabolites in various left ventricular heart diseases, however, mainly for technical and sensitivity reasons, its successful transfer for measurements in the RV is currently missing. In the present study, the usefulness of this non-invasive approach is not only shown in RV failure due to PAH but also tested during subsequent therapy.